Asset Details
Do you wish to reserve the book?
Akkermansia muciniphila Alleviates Olanzapine‐Induced Hepatic Steatosis via the Gut Microbiota‐IGFBP2/APOA1‐Liver Axis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Akkermansia muciniphila Alleviates Olanzapine‐Induced Hepatic Steatosis via the Gut Microbiota‐IGFBP2/APOA1‐Liver Axis
Do you wish to request the book?
Akkermansia muciniphila Alleviates Olanzapine‐Induced Hepatic Steatosis via the Gut Microbiota‐IGFBP2/APOA1‐Liver Axis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Akkermansia muciniphila Alleviates Olanzapine‐Induced Hepatic Steatosis via the Gut Microbiota‐IGFBP2/APOA1‐Liver Axis
2025
Overview
Olanzapine is associated with a high risk of hepatic steatosis as a commonly used atypical antipsychotic. In this study, we observed differential susceptibility to olanzapine‐induced fatty liver disease in both rats and patients. Notably, patients with olanzapine‐induced liver damage exhibited an altered gut microbiota composition, with Akkermansia muciniphila showing the most pronounced alteration. To explore its therapeutic potential, we administered A. muciniphila to olanzapine‐treated rats, which significantly reduced hepatic lipid accumulation and liver injury. Gut microbiome analysis revealed significant alterations in microbial diversity and composition following A. muciniphila treatment. Transcriptomic analysis further identified differentially expressed genes in the liver, highlighting the involvement of IGFBP2 and APOA1 in the protective effects of A. muciniphila . Functional validation demonstrated that overexpression of IGFBP2 and APOA1 alleviated olanzapine‐induced hepatic steatosis in both cellular and animal models. These findings suggest that A. muciniphila exerts hepatoprotective effects via the gut microbiota‐IGFBP2/APOA1‐liver axis, offering a potential microbiota‐targeted strategy to mitigate olanzapine‐induced metabolic dysfunction. Olanzapine induces hepatic steatosis with differential susceptibility observed in both rats and patients, while A. muciniphila alleviates liver lipid accumulation and injury by modulating gut microbiota and hepatic gene expression. Overexpression of IGFBP2 and APOA1 further protects against olanzapine‐induced hepatic steatosis.
Publisher
John Wiley & Sons, Inc,Wiley
Subject
/ Animals
/ Antipsychotic Agents - adverse effects
/ Apolipoprotein A-I - genetics
/ Apolipoprotein A-I - metabolism
/ Fatty Liver - chemically induced
/ Females
/ Gastrointestinal Microbiome - drug effects
/ Humans
/ Insulin-like growth factor-binding protein 2
/ Lipids
/ Liver
/ Male
/ Olanzapine - adverse effects
/ Rats
We currently cannot retrieve any items related to this title. Kindly check back at a later time.